VIR News and Press, Vir Biotechnology Inc.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...

2024-07-17 16:47:26 ET Summary VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unm...

2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...

2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...

2024-07-04 10:01:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That’s because most retail investors prefer to research consumer info...

Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that ...

2024-06-06 11:36:47 ET Summary Today, we put diagnostic company Fulgent Genetics, Inc. back in the spotlight as sales growth is returning after navigating a "Covid Cliff." While the company is still losing money, the stock is trading for less than the net cash on Fulgent's balance...

2024-06-05 19:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VIR on June 5, 2024 05:15PM ET. The previous analyst recommendation was Equal-Weight. VIR was trading at $12.66 at issue of the analyst recommendation. The overall analyst consensus : BU...

2024-06-05 17:00:05 ET Michael Ulz from Morgan Stanley issued a price target of $15.00 for VIR on 2024-06-05 14:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VIR was trading at $12.66. The overall price target consensus is at $30.13...

2024-06-05 08:46:27 ET Read the full article on Seeking Alpha For further details see: Vir gains on early mid-stage data for hepatitis candidate